Success Metrics

Clinical Success Rate
100.0%

Based on 10 completed trials

Completion Rate
100%(10/10)
Active Trials
0(0%)
Results Posted
10%(1 trials)

Phase Distribution

Ph phase_2
2
20%
Ph phase_3
7
70%
Ph phase_1
1
10%

Phase Distribution

1

Early Stage

2

Mid Stage

7

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
1(10.0%)
Phase 2Efficacy & side effects
2(20.0%)
Phase 3Large-scale testing
7(70.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

10 of 10 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(10)

Detailed Status

Completed10

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (10.0%)
Phase 22 (20.0%)
Phase 37 (70.0%)

Trials by Status

completed10100%

Recent Activity

0 active trials
Showing 5 of 10
completedphase_2

Study to Demonstrate Cognitive Enhancing Effects of BF2.649

NCT00690274
completedphase_3

Long Term Open Label Study in Narcolepsy With BF2.649 (Pitolisant)

NCT01399606
completedphase_3

Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy.

NCT01638403
completedphase_3

Patient Narcoleptic Treated With BF2.649 (Pitolisant) in add-on to Sodium Oxybate (HARMONY IV)

NCT01789398
completedphase_3

BF2.649 in Patients With OSA and Treated by CPAP But Still Complaining of EDS

NCT01071876
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT00690274Phase 2

Study to Demonstrate Cognitive Enhancing Effects of BF2.649

Completed
NCT01399606Phase 3

Long Term Open Label Study in Narcolepsy With BF2.649 (Pitolisant)

Completed
NCT01638403Phase 3

Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy.

Completed
NCT01789398Phase 3

Patient Narcoleptic Treated With BF2.649 (Pitolisant) in add-on to Sodium Oxybate (HARMONY IV)

Completed
NCT01071876Phase 3

BF2.649 in Patients With OSA and Treated by CPAP But Still Complaining of EDS

Completed
NCT01072968Phase 3

BF2.649 in Patients With OSA, Still Complaining of EDS and Refusing to be Treated by CPAP.

Completed
NCT01619033Phase 1

Pharmacokinetics of BF2.649 in Renal Impairment

Completed
NCT01067235Phase 3

Efficacy and Safety Study of BF2.649 and BF2.649 Add on Modafinil on Cataplexy in Patients With Narcolespy

Completed
NCT01620554Phase 2

Dose-range Finding Study of BF2.649 Effect on Patients With Obstructive Sleep Apnea (OSA)

Completed
NCT01067222Phase 3

Efficacy and Safety Study of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10